Changes

Jump to: navigation, search

Erdafitinib (Balversa)

17 bytes added, 15:00, 12 May 2019
m
typo
==General information==
Class/mechanism: Tyrosine kinase inhibitor of . Erdafitinib inhibits multiple receptor tyrosine kinases (RTKs), including fibroblast growth factor receptors (FGFR) FGFR1, FGFR2, FGFR3, FGFR4, as well as RET, CSF1R, PDGFRA, PDGFRB, FLT4, KIT, and VEGFR2. Erdafinitinib Erdafitinib inhibits FGFR-related phosphorylation and signal transduction, resulting in inhibition and tumor cell death in FGFR-overexpressing tumor cells.<ref name="insert">[http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/BALVERSA-pi.pdf Erdafitinib (Balversa) package insert]</ref><ref>[[Media:ErdafinitibErdafitinib.pdf| Erdafitinib (Balversa) package insert (locally hosted backup)]]</ref><ref>[https://www.balversa.com/ Balversa manufacturer's website]</ref>
<br>Route: PO
<br>Extravasation: n/a
LookupUsers, editors, emailconfirmed
3,827
edits

Navigation menu